Rheumatology
Conference Coverage
Mavrilimumab may aid severe COVID-19 recovery
The granulocyte/macrophage-colony stimulating factor (GM-CSF) blocker reduced the need for mechanical ventilation and death by day 29 versus...
Conference Coverage
Hypertension worsened by commonly used prescription meds
Close to 20% of U.S. adults with hypertension are on a prescription drug, such as NSAIDs, known to raise blood pressure, creating an opportunity...
Conference Coverage
To improve psoriatic arthritis outcomes, address common comorbidities
Depression and obesity are associated with poor treatment response in PsA.
News
Bone loss common in kidney stone patients, yet rarely detected
Almost one-quarter of patients diagnosed with kidney stones have osteoporosis or a fracture history on diagnosis, yet few undergo bone mineral...
Conference Coverage
OA risk-reduction program targets injured knees
The Stop Osteoarthritis program is currently testing the feasibility of a three-part intervention to help prevent posttraumatic knee OA.
News
COVID-19 vaccination recommended for rheumatology patients
The threat posed by COVID-19 for people with rheumatic diseases outweighs concerns about vaccination against SARS-CoV-2, says the American College...
Conference Coverage
Pandemic puts patients with psoriatic disease off seeking medical help
Both the physical and mental health of people with psoriasis and psoriatic arthritis has been affected by the ongoing COVID-19 pandemic.
Conference Coverage
Romosozumab may not increase cardiovascular risk after all
Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box...
News
Outcomes have improved for PAH in connective tissue disease
Modern treatments and combination approaches may have contributed to overall improvements in survival in patients with pulmonary arterial...
News
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseases
A Dutch nationwide study in melanoma patients found relative safety of immune checkpoint inhibitors for grade 3 immune-related AEs but does not...